SG Americas Securities
HAE icon

SG Americas Securities’s Haemonetics HAE Stock Holding History

SG Americas Securities’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27,400
Closed -$4K – 3391
2020
Q3 		$4K Buy
+27,400
New +$2.39M ﹤0.01% 2613

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SG Americas Securities's HAE Position: Q1 2026 in Review

SG Americas Securities reduced its Haemonetics (HAE) stake by 68% in Q1 2026, selling an estimated $630K and leaving 4,540 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #2528.

SG Americas Securities first reported a position in HAE in Q3 2013 and has held it in 39 quarters since. The position peaked at $14.2M in Q1 2020. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • SG Americas Securities held 4,540 shares of Haemonetics worth $256K as of Q1 2026.
  • SG Americas Securities sold 9,679 Haemonetics shares in Q1 2026, an estimated $630K.
  • Haemonetics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2528 holding.
  • SG Americas Securities first reported a position in Haemonetics in Q3 2013 and has held it in 39 quarters since.
  • SG Americas Securities's Haemonetics position peaked at $14.2M in Q1 2020.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.